Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 13;12(7):770.
doi: 10.3390/vaccines12070770.

Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis

Maria Elena Flacco  1 , Alessandro Bianconi  2 , Giovanni Cioni  1 , Matteo Fiore  2 , Giovanna Letizia Calò  1 , Gianmarco Imperiali  1 , Vittorio Orazi  1 , Marco Tiseo  1 , Anastasia Troia  1 , Annalisa Rosso  1 , Lamberto Manzoli  2
Affiliations
Review

Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis

Maria Elena Flacco et al. Vaccines (Basel). .

Abstract

The TAK-003 dengue vaccine was licensed in Europe in December 2022, and the official recommendations from most EU countries are still under formulation. To support policymakers, we performed a meta-analysis to quantify TAK-003's immunogenicity, efficacy and safety among seronegative and seropositive populations after the administration of one or two vaccine doses. We included trials retrieved from MEDLINE, Scopus and ClinicalTrials.gov. The outcomes were the rates of seroconversion, virologically confirmed dengue fever and serious adverse events after each vaccine dose. Data were combined using random-effect proportion or head-to-head meta-analyses. We retrieved a total of 19 datasets, including >20,000 participants. TAK-003 showed an excellent safety profile, and the immunogenicity after two doses against the four DENV serotypes was ≥90% among both adults and children/adolescents who were either seronegative or seropositive at baseline. A single dose was able to elicit a high immunogenic response among adults (≥70%) and children/adolescents (≥90%). The primary two-dose immunization course halved the risk of all types of virologically confirmed dengue fever among seropositive children/adolescents, but seronegative minors were only protected against the diseases caused by DENV-1 and DENV-2. Overall, the results support the use of TAK-003 for the prevention of dengue fever in the pediatric population of endemic countries. Uncertainties remain on the use of a single vaccine dose in non-endemic countries.

Keywords: TAK-003; dengue fever; dengue vaccine; immunogenicity; meta-analysis; vaccine efficacy; vaccine safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA 2009 flow diagram.
See this image and copyright information in PMC

References

    1. Tricou V., Saez-Llorens X., Yu D., Rivera L., Jimeno J., Villarreal A.C., Dato E., Saldana de Suman O., Montenegro N., DeAntonio R., et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: A randomised, placebo-controlled, phase 2 trial. Lancet. 2020;395:1434–1443. doi: 10.1016/S0140-6736(20)30556-0. - DOI - PubMed
    1. Wilder-Smith A. TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden. Lancet Glob. Health. 2024;12:e179–e180. doi: 10.1016/S2214-109X(23)00590-9. - DOI - PubMed
    1. Paz-Bailey G., Adams L.E., Deen J., Anderson K.B., Katzelnick L.C. Dengue. Lancet. 2024;403:667–682. doi: 10.1016/S0140-6736(23)02576-X. - DOI - PubMed
    1. Tricou V., Yu D., Reynales H., Biswal S., Saez-Llorens X., Sirivichayakul C., Lopez P., Borja-Tabora C., Bravo L., Kosalaraksa P., et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob. Health. 2024;12:e257–e270. doi: 10.1016/S2214-109X(23)00522-3. - DOI - PubMed
    1. Saez-Llorens X., Tricou V., Yu D., Rivera L., Jimeno J., Villarreal A.C., Dato E., Mazara S., Vargas M., Brose M., et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect. Dis. 2018;18:162–170. doi: 10.1016/S1473-3099(17)30632-1. - DOI - PubMed

LinkOut - more resources